Human immunodeficiency virus type 1 Pol polyprotein (HIV-1 Pol) (HIV-1 Pol)

The HIV-1 Pol polyprotein is a precursor protein that is cleaved into three essential enzymes: protease (PR), reverse transcriptase (RT), and integrase (IN) (UniProt: P03366). These enzymes are critical for the replication cycle of the Human Immunodeficiency Virus type 1, the causative agent of AIDS (PubMed: 1757266). Reverse transcriptase converts the viral RNA genome into DNA, while integrase inserts this DNA into the host cell's genome to establish a persistent infection (PubMed: 25849340). Protease is responsible for the maturation of viral particles by cleaving polyprotein precursors into functional structural and enzymatic proteins (StatPearls: HIV-1 Protease Inhibitors). Because of their vital roles, these three enzymes are the primary targets of highly active antiretroviral therapy (HAART), which utilizes combinations of inhibitors to suppress viral replication (NIH: HIV Treatment). Drugs targeting these enzymes include nucleoside and non-nucleoside reverse transcriptase inhibitors, protease inhibitors, and integrase strand transfer inhibitors. Clinical management of HIV involves monitoring viral load and CD4+ counts, as well as screening for resistance mutations that can render these drugs ineffective (PubMed: 30124164). Despite the success of these therapies, long-term use is associated with safety concerns such as metabolic disturbances, renal toxicity, and the potential for multi-drug resistance (StatPearls: Antiretroviral Therapy).

Other names

HIV-1 Pol proteinHIV-1 polymeraseHIV-1 RT/PR/INHIV-1 reverse transcriptase / protease / integrase

Inhibition of viral DNA synthesis (RTIs), inhibition of viral polyprotein cleavage (PIs), and inhibition of viral DNA integration into the host genome (INSTIs) (NIH: Antiretroviral Drug Discovery).